论文部分内容阅读
目的探讨上皮性卵巢癌中糖皮质激素诱导的亮氨酸拉链蛋白(GILZ)、Y-盒结合蛋白1(YB-1)和P-糖蛋白(P-gp)的蛋白表达,分析其与卵巢癌化疗耐药的关系。方法 2005年3月至2012年2月在大连医科大学第一、第二附属医院采用免疫组织化学SP法检测85例上皮性卵巢癌,30例卵巢良性肿瘤和12例正常卵巢组织中GILZ、YB-1和PGP的蛋白表达情况,并结合临床病理资料进行综合分析。结果 GILZ、YB-1和P-gp在上皮性卵巢癌中表达阳性率分别为51.8%、48.2%和47.1%,在卵巢良性肿瘤和正常卵巢组织中均未见表达,差异有统计学意义(P<0.01)。YB-1和P-gp在Ⅲ~Ⅳ期上皮性卵巢癌中的表达高于Ⅰ~Ⅱ上皮性卵巢癌中的表达(P<0.05)。GILZ、YB-1和P-gp三者相关,GILZ与YB-1,r=0.344;P-gp与GILZ,r=0.437;P-gp与YB-1,r=0.570(P均<0.01)。44例GILZ蛋白阳性表达者中18例为化疗耐药,41例GILZ蛋白阴性表达者中6例为化疗耐药,差异有统计学意义(P<0.05)。41例YB-1蛋白阳性表达者中17例为化疗耐药,44例YB-1蛋白阴性表达者中7例为化疗耐药,差异有统计学意义(P<0.05)。40例P-gp蛋白阳性表达者中17例为化疗耐药,45例P-gp蛋白阴性表达者中7例为化疗耐药,差异有统计学意义(P<0.05)。结论 GILZ、YB-1和P-gp可能参与了卵巢癌的发生、发展过程。3种蛋白在卵巢癌化疗耐药中发挥一定作用,独立或联合检测可能预测化疗的敏感性。
Objective To investigate the expression of glucocorticoid-induced leucine zipper protein (GILZ), Y-box binding protein 1 (YB-1) and P-glycoprotein (P-gp) in epithelial ovarian cancer Cancer chemoresistance relationship. Methods From March 2005 to February 2012, immunohistochemical SP method was used in 85 cases of epithelial ovarian cancer, 30 cases of benign ovarian tumor and 12 cases of normal ovarian tissue in the First and Second Affiliated Hospital of Dalian Medical University to detect GILZ, YB -1 and PGP protein expression, combined with clinical and pathological data for a comprehensive analysis. Results The positive rates of GILZ, YB-1 and P-gp in epithelial ovarian cancer were 51.8%, 48.2% and 47.1%, respectively, which were not found in benign ovarian tumors and normal ovarian tissues, the difference was statistically significant P <0.01). The expression of YB-1 and P-gp in stage Ⅲ-Ⅳ epithelial ovarian cancer was higher than that in stage Ⅰ-Ⅱ epithelial ovarian cancer (P <0.05). GILZ, YB-1 and P-gp, GILZ and YB-1, r = 0.344; P-gp and GILZ, r = 0.437; P-gp and YB- . Among the 44 cases with GILZ protein positive, 18 cases were resistant to chemotherapeutic drugs, and 6 of 41 cases with negative GILZ protein were resistant to chemotherapy. The difference was statistically significant (P <0.05). Seventeen of the 41 patients with YB-1 protein expression were chemoresistant, and 7 of 44 patients with YB-1 protein expression were resistant to chemotherapy. The difference was statistically significant (P <0.05). Among the 40 cases with P-gp expression, 17 cases were resistant to chemotherapeutic drugs, and 7 of 45 cases with negative P-gp protein were chemoresistant. The difference was statistically significant (P <0.05). Conclusion GILZ, YB-1 and P-gp may be involved in the occurrence and development of ovarian cancer. The three proteins play a role in chemoresistance in ovarian cancer, and independent or combined testing may predict chemosensitivity.